Gemcitabine
- Generic Name
- Gemcitabine
- Brand Names
- Gemzar
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11F2N3O4
- CAS Number
- 95058-81-4
- Unique Ingredient Identifier
- B76N6SBZ8R
- Background
Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...
- Indication
Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.
In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...
- Associated Conditions
- Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
- Associated Therapies
- -
A Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT00191347
- Locations
- 🇨🇦
For additional information regarding investigative sites for thsi trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Ontario, Canada
Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT00191841
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ufa, Russian Federation
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-11-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 69
- Registration Number
- NCT00193453
- Locations
- 🇺🇸
Gainsville Hematology Oncology Associates, Gainesville, Florida, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-07-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT00193362
Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-06-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 346
- Registration Number
- NCT00193323
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 72
- Registration Number
- NCT00193414
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
Chemoradiotherapy in Patients With Localised Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2014-08-04
- Lead Sponsor
- Trans Tasman Radiation Oncology Group
- Target Recruit Count
- 82
- Registration Number
- NCT00193921
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺Mater Misericordiae Hospital, Brisbane, Queensland, Australia
🇦🇺Calvary Mater Newcastle, Newcastle, New South Wales, Australia
Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 263
- Registration Number
- NCT00191126
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician., Taichung, Taiwan
Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 96
- Registration Number
- NCT00193076
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-03-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 919
- Registration Number
- NCT00191646
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.